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Abstract
Background: Fasting has dramatic effects on small intestinal transport function. However, little is
known on expression of intestinal transport and phase I/II metabolism genes during fasting and the
role the fatty acid-activated transcription factor PPARα may play herein. We therefore investigated
the effects of fasting on expression of these genes using Affymetrix GeneChip MOE430A arrays
and quantitative RT-PCR.
Results: After 24 hours of fasting, expression levels of 33 of the 253 analyzed transporter and
phase I/II metabolism genes were changed. Upregulated genes were involved in transport of energy-
yielding molecules in processes such as glycogenolysis (G6pt1) and mitochondrial and peroxisomal
oxidation of fatty acids (Cact,  Mrs3/4,  Fatp2,  Cyp4a10,  Cyp4b1). Other induced genes were
responsible for the inactivation of the neurotransmitter serotonin (Sert, Sult1d1, Dtd, Papst2),
formation of eicosanoids (Cyp2j6, Cyp4a10, Cyp4b1), or for secretion of cholesterol (Abca1 and
Abcg8). Cyp3a11, typically known because of its drug metabolizing capacity, was also increased.
Fasting had no pronounced effect on expression of phase II metabolic enzymes, except for
glutathione S-transferases which were down-regulated. Time course studies revealed that some
genes were acutely regulated, whereas expression of other genes was only affected after prolonged
fasting. Finally, we identified 8 genes that were PPARα-dependently upregulated upon fasting.
Conclusion: We have characterized the response to fasting on expression of transporters and
phase I/II metabolic enzymes in murine small intestine. Differentially expressed genes are involved
in a variety of processes, which functionally can be summarized as a) increased oxidation of fat and
xenobiotics, b) increased cholesterol secretion, c) increased susceptibility to electrophilic
stressors, and d) reduced intestinal motility. This knowledge increases our understanding of gut
physiology, and may be of relevance for e.g. pre-surgery regimen of patients.
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Background
Fasting, the act of willingly abstaining from food, is a fre-
quently occurring natural status in humans. Fasting is a
popular strategy to manage overweight or obesity, it is a
traditional habit in certain religions or societies, and it is
an accepted pre-surgical procedure. During fasting whole-
body fuel utilization gradually shifts from carbohydrates
and fat in the fed state to proteins and fat after a day of
fasting [1]. The nuclear receptor peroxisome proliferator-
activated receptor alpha (PPARα) plays an important role
in the control of the hepatic metabolic response [2]. Dur-
ing fasting, free fatty acid levels in plasma are elevated and
can activate PPARα, which regulates a large array of
hepatic genes including those involved in fatty acid catab-
olism.
The small intestine is the primary organ for digestion and
selective absorption of nutrients and other food constitu-
ents. Absorption of these molecules across the intestinal
epithelium occurs mainly by multiple transmembrane
transporters [3-6] that principally belong to two super-
families, namely the solute carrier (SLC) and the ATP
Binding Cassette (ABC) superfamily of transporters [5,7].
SLC transporters located at the apical membrane of the
enterocyte are responsible for the selective uptake of
macronutrients, such as di- and tripeptides, hexoses and
fatty acids [8]. In contrast, ABC transporters are efflux
transporters responsible for the active removal of sub-
stances, including nutrients such as cholesterol, limiting
their intracellular concentrations. Besides their presence
in plasma membranes, SLC and ABC transporters are also
located in intracellular organelles, such as mitochondria
or peroxisomes, in which they are responsible for uptake
or secretion of metabolites.
In addition, it has become clear that the intestinal epithe-
lium is an important metabolic site, to a great extend
responsible for the first-pass metabolism of nutrients and
xenobiotics [9,10]. Numerous metabolic reactions occur
in enterocytes, including those typically referred to as
phase I and phase II metabolism. Phase I metabolism
commonly refers to oxidative, peroxidative, and reductive
metabolism of endogenous compounds and drugs, medi-
ated by cytochrome P450 isoenzymes (CypP450s) [11].
Phase II metabolism often succeed phase I metabolism
and is mediated by several enzymatic systems. In general,
phase II metabolism yields conjugated metabolites,
increasing the water solubility of lipophilic compounds.
The most important phase II enzymes are sulfotrans-
ferases (Sults) [12,13], UDP-glucuronosyltransferases
(Ugts) [14], glutathione S-transferases (Gsts) [15,16], N-
acetyltransferases (Nats) [17], and epoxide hydrolases
(Ephs) [18]. Several ABC transporters can secrete metabo-
lites resulting from phase I and phase II enzymatic trans-
formations [19].
Previous studies showed that fasting has a dramatic effect
on small intestinal transport function [20]. However, little
is known on the expression of transport and phase I/II
metabolism genes in small intestine during fasting and
the role of PPARα therein. We therefore set out to investi-
gate the effects of fasting on expression of these genes
using microarrays and quantitative RT-PCR (qRT-PCR).
We conclude that the absorptive as well as the detoxifica-
tion capacity of the small intestine is altered during fast-
ing, and that PPARα mediates a part of the adaptive
response to fasting.
Results
Effect of 24 hours of fasting on expression of transporter 
and phase I/II metabolism genes
The Affymetrix GeneChip Mouse Genome 430A array
comprises 22,690 probesets, representing 12,453 unique
genes. Annotation information from Affymetrix was que-
ried to compile a list of transporter and phase I/II metab-
olism genes present on the array (for details, see
Methods). This list consisted of 665 probesets, encoding
for 436 unique genes, and was used in the remainder of
our analyses (Table 1). Under basal, chow-fed conditions,
our filtering protocol identified 5,993 significantly
expressed genes in the small intestine (i.e. having an abso-
lute expression signal >20), of which 253 were transport-
ers and phase I/II metabolism genes. After 24 hours of
fasting, 713 genes, including 33 transporter and phase I/II
metabolism genes, were differentially expressed (fold
change >1.3, p-value < 0.01), corresponding to 13% of the
expressed transporter and phase I/II metabolism genes.
For selected genes additional qRT-PCR analyses were per-
formed, which confirmed the array results (Table 2).
Table 1: Numbers of expressed and regulated genes in small intestine analyzed on Affymetrix GeneChip MOE430A arrays.
All genes Transporters + phase I/II metabolism genes
Number of probe sets on MOE430A array 22690 665
Number of unique genes on MOE430A array 12453 436
Expressed genes on MOE430A array 5993 253
Regulated after 24 hours of fasting 713 33
Regulated genes, as % of expressed genes 11.8 13.0
Analysis of all genes on the MOE430A array compared with transporters and phase I/II metabolism genes.BMC Genomics 2007, 8:267 http://www.biomedcentral.com/1471-2164/8/267
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Table 2: Confirmation of microarray results.
Gene symbol Affy probe 
set ID
FC 
microarray
P-value 
microarray
FC qRT-PCR P-value 
qRT-PCR
Gene name
Cyp4a10 1424853_s_at 3.6 0.0019 2.5 ± 0.34 0.0172 cytochrome P450, family 4, subfamily a, polypeptide 10
Cyp2j6 1417952_at 2.3 0.0000 1.7 ± 0.32 0.0435 cytochrome P450, family 2, subfamily j, polypeptide 6
Abca1 1421840_at 2.3 0.0005 2.4 ± 0.26 0.0330 ATP-binding cassette, sub-family A (ABC1), member 1
G6pt1 (Slc37a4) 1417042_at 2.3 0.0010 1.9 ± 0.20 0.0086 solute carrier family 37 (glycerol-6-phosphate 
transporter), member 4
Znt2 (Slc30a2) 1427339_at 1.9 0.0002 1.6 ± 0.24 0.0383 solute carrier family 30 (zinc transporter), member 2
Abcg8 1420656_at 1.8 0.0003 1.7 ± 0.29 0.0492 ATP-binding cassette, sub-family G (WHITE), member 8
Sult1d1 1418138_at 1.7 0.0017 1.8 ± 0.33 0.0310 sulfotransferase family 1D, member 1
Fatp2 (Slc27a2) 1416316_at 1.6 0.0003 2.0 ± 0.24 0.0283 solute carrier family 27 (fatty acid transporter), member 2
Nadc1 (Slc13a2) 1418857_at 1.6 0.0011 1.6 ± 0.13 0.0247 solute carrier family 13 (sodium-dependent dicarboxylate 
transporter), member 2
Slc25a36 1419656_at 1.5 0.0007 2.0 ± 0.19 0.0114 solute carrier family 25, member 36
Chst4 1453393_a_at 1.4 0.0008 1.6 ± 0.13 0.0142 carbohydrate (chondroitin 6/keratan) sulfotransferase 4
Dtd (Slc26a2) 1421145_at 1.4 0.0028 1.5 ± 0.06 0.0017 solute carrier family 26 (sulfate transporter), member 2
Mrs3/4 (Slc25a28) 1424776_a_at 1.4 0.0018 1.5 ± 0.08 0.0141 solute carrier family 25, member 28
Mgst1 1415897_a_at 1.3 0.0014 2.0 ± 0.21 0.0078 microsomal glutathione S-transferase 1
Cyp3a11 1416809_at 1.3 0.0057 1.9 ± 0.22 0.0149 cytochrome P450, family 3, subfamily a, polypeptide 11
Mct4 (Slc16a3) 1449005_at -1.6 0.0058 -1.6 ± 0.00 0.0329 solute carrier family 16 (monocarboxylic acid 
transporters), member 3
Zip4 (Slc39a4) 1451139_at -2.4 0.0003 -2.2 ± 0.18 0.0472 solute carrier family 39 (zinc transporter), member 4
Gstm3 1427473_at -2.6 0.0027 -2.2 ± 0.08 0.0338 glutathione S-transferase, mu 3
Microarray results were confirmed with qRT-PCR. FC = Fold change, qRT-PCR control samples have been set arbitrarily to 1, qRT-PCR data are 
means ± standard error (n = 3).
Solute carrier transporters
We studied 243 SLC transporters, which amounts to 68%
of the total number transporters of this superfamily cur-
rently known (see additional file 1). After 24 hours of fast-
ing, 16 SLC transporters were differentially expressed
(Table 3), which corresponded to 15% of the expressed
SLC transporter genes in the small intestine. With respect
to apical transporters, expression of the short-chain fatty
acid transporter Smct1  (Slc5a8) [21], the carboxylate
transporter Nadc1 (Slc13a2) [22], the prostaglandin trans-
porter Pgt (Slco2a1) [23], and the sulphate transporter Dtd
(Slc26a2) [24] was increased, whereas the expression level
of the zinc transporter Zip4  (Slc39a4) [25] was sup-
pressed. The basolaterally located monocarboxylate trans-
porter  Mct4  (Slc16a3) [26] and iron transporter Ireg1
(Slc40a1) [27] were downregulated, and the basolateral
neurotransmitter serotonin transporter Sert  (Slc6a4/5-
HTT) [28], was upregulated. Seven intracellular SLC trans-
porters were induced (Table 3); Znt2  (Slc30a2),  G6pt1
(Slc37a4),  Fatp2  (Slc27a2),  Papst2  (Slc35b3),  Cact
(Slc25a20), Mrs3/4 (Slc25a28), and Slc25a36. Znt2 [29] is
responsible for storage of zinc in sub-apically-located ves-
icles. G6pt1 [30] and Fatp2 [31] are localized at the endo-
plasmic reticulum, transporting glucose-6 phosphate and
fatty acyl-CoA esters, respectively. The sulphate donor 3'-
phosphoadenosine 5'-phosphosulfate (PAPS) transporter
Papst2 [32] is localized in the Golgi. Finally, Cact, Mrs3/4
and Slc25a36 are all three present in mitochondria shut-
tling metabolites across the inner mitochondrial mem-
brane [33]. Cact and Mrs3/4 transport fatty acyl carnitines
for fatty acid oxidation and iron, respectively. The func-
tion of Slc25a36 is currently not known. Finally, Fuct1
(Slc35c1) [34] an additional member of the Slc35 family,
transporting nucleotide sugars, was downregulated.
Phase I and II metabolic genes
Next we evaluated the effects of fasting on expression of
phase I/II metabolism genes (see additional file 2).
Results are presented in Table 4. We studied 61 CypP450s,
which corresponds to 66% of the currently known mouse
CypP450s. Five CypP450s were differentially expressed,
corresponding to 29% of the expressed CypP450s in small
intestine. Cyp2j6 was upregulated. Members of the Cyp2
family are well known to be responsible for the NADPH-
dependent oxidation of steroids and fatty acid as well as
drugs [11]. In addition, expression of Cyp3a11, typically
known because of its drug-metabolizing capacity [11],
was increased. Finally, Cyp4a10 and Cyp4b1, involved in
peroxisomal oxidation of fatty acids, and Cyp27a1,
involved in conversion of cholesterol into 27-hydroxyc-
holesterol, were all induced upon fasting [11,35,36]. With
respect to phase II metabolism, expression of in total 89
enzymes was analyzed (see additional file 2). Except for
Gsts, fasting had no denoting effect on expression of
phase II metabolism genes (Table 4), since only 3 non-
Gsts were changed. Apart from Gstm1, all changed Gsts
were downregulated. The aldo-keto reductase Akr1b7 [37],
involved in detoxification of lipid peroxides, and two sul-
fotransferases, Sult1d1 and Chst4, were increased.
ABC transporters
Effects of fasting on expression of ABC transporters are
summarized in Table 5. We analyzed 40 of the 52 murine
ABC transporters (see additional file 3). The transportersBMC Genomics 2007, 8:267 http://www.biomedcentral.com/1471-2164/8/267
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Table 3: Differential expressed SLC transporters in the small intestine after 24 h fasting.
Gene symbol Affy probe 
set ID
A 
value
SD WT 
0 hr
SD WT 
24 hr
Fold 
change
P-
value
Localization Gene name
G6pt1 (Slc37a4) 1417042_at 7.7 0.44 0.37 2.3 0.0010 Endoplasmatic reticulum Solute carrier family 37 (glycerol-6-
phosphate transporter), member 4
Znt2 (Slc30a2) 1427339_at 5.6 0.09 0.30 1.9 0.0002 Vesicles Solute carrier family 30 (zinc transporter), 
member 2
Slc25a36 1419656_at 6.7 0.09 0.22 1.7 0.0002 Mitochondria Solute carrier family 25, member 36
Fatp2(Slc27a2) 1416316_at 10.4 0.19 0.11 1.6 0.0003 Peroxisomes and ER Solute carrier family 27 (fatty acid 
transporter), member 2
Nadc1 (Slc13a2) 1418857_at 10.2 0.23 0.15 1.6 0.0011 Apical Solute carrier family 13 (sodium-
dependent dicarboxylate transporter), 
member 2
Slc25a36 1419657_a_at 9.4 0.16 0.14 1.5 0.0007 Mitochondria Solute carrier family 25, member 36
Papst2 (Slc35b3) 1448937_at 7.6 0.04 0.18 1.5 0.0005 Golgi Solute carrier family 35, member B3
Smct1 (Slc5a8) 1425606_at 6.5 0.14 0.12 1.5 0.0009 Apical Solute carrier family 5 (iodide 
transporter), member 8
Cact (Slc25a20) 1423108_at 9.2 0.04 0.07 1.4 0.0002 Mitochondria Solute carrier family 25 (mitochondrial 
carnitine/acylcarnitine translocase), 
member 20
Cact (Slc25a20) 1423109_s_at 7.9 0.10 0.19 1.4 0.0019 Mitochondria Solute carrier family 25 (mitochondrial 
carnitine/acylcarnitine translocase), 
member 20
Sert (Slc6a4) 1417150_at 8.5 0.18 0.07 1.4 0.0014 Basolateral Solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4
Mrs3/4 (Slc25a28) 1424776_a_at 7.0 0.12 0.17 1.4 0.0018 Mitochondria Solute carrier family 25, member 28
Dtd (Slc26a2) 1421145_at 5.6 0.06 0.22 1.4 0.0028 Apical Solute carrier family 26 (sulfate 
transporter), member 2
Oatp2a1 (Slco2a1) 1420913_at 8.3 0.06 0.17 1.4 0.0023 Apical Solute carrier organic anion transporter 
family, member 2a1
Fuct1 (Slc35c1) 1452139_at 7.3 0.16 0.36 -1.4 0.0052 Golgi Solute carrier family 35, member C1
Ireg1 (Slc40a1) 1417061_at 8.1 0.38 0.35 -1.6 0.0099 Basolateral Solute carrier family 40 (iron-regulated 
transporter), member 1
Mct4 (Slc16a3) 1449005_at 4.2 0.44 0.21 -1.6 0.0058 Basolateral Solute carrier family 16 (monocarboxylic 
acid transporters), member 3
Ireg1 (Slc40a1) 1448566_at 7.8 0.48 0.50 -1.7 0.0084 Basolateral Solute carrier family 40 (iron-regulated 
transporter), member 1
Zip4 (Slc39a4) 1451139_at 9.0 0.04 0.48 -2.0 0.0003 Apical Solute carrier family 39 (zinc transporter), 
member 4
A = the average log2 transformed expression value of normal fed and 24 hours fasted mice (n = 3), SD = standard deviation, WT = wild-type mice. In addition to 
the fold change, the intracellular localization of the corresponding protein is given.
Abca1 [38], involved in basolateral efflux of cholesterol,
and  Abcg8  [39], involved in transport of sterols and
stanols across the apical membrane, were upregulated.
Time dependent changes of gene expression during fasting
To get insight into the time-dependent effects of fasting,
we performed an additional experiment in which mice
were deprived of food for various time points up to 24
hours. Intestinal weight, blood glucose and plasma free
fatty acid levels were measured (Figure 1). As expected,
blood glucose levels decreased until 12 hours of fasting,
after which it stabilized [2]. Free fatty acid levels rapidly
increased at the onset of fasting, and remained constant
after 18 hours. Intestinal weight decreased already after 3
hours of fasting, significant changes were found as from
12 hours of fasting. For selected transporters and phase I/
II metabolism enzymes gene expression was measured
using qRT-PCR (Figure 2). Genes were selected based on
function and array data. Several genes were regulated
gradually in time and seemed to follow the same pattern
as the free fatty acid concentration (Fatp2, Znt2, G6pt1,
Zip4, Cyp27a1, Cyp2j6, and Sult1d1). Other genes were
acutely regulated (Nadc1, Znt2, Zip4, Cyp27a1, Sult1d1,
Gstm3, and Abca1.) In this group Nadc1 and Gstm3 were
most drastic regulated after 3 hours fasting. Finally, a
group of genes responded only after prolonged fasting
(G6pt1,  Fatp2,  Mct4,  Cyp4a10,  Cyp3a11,  Cyp2j6, and
Abcg8). These data indicate that different mechanisms
underlay the response to fasting.
Role of PPARα during fasting
It has been shown that PPARα is an important mediator
of the hepatic adaptive response to fasting [2]. Therefore
we evaluated the role of this transcription factor in regu-
lating transporter and phase I/II metabolism genes in
small intestine during fasting. To this end, the effect of 24
hours fasting was compared in wild-type and PPARα
knockout mice (Table 6). Eight of the genes identified in
wild-type mice were PPARα-dependently regulated,
which corresponded to 24% of all genes regulated. No
genes were found to be suppressed in a PPARα dependentBMC Genomics 2007, 8:267 http://www.biomedcentral.com/1471-2164/8/267
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manner. qRT-PCR was used to confirm the differential
expression of Cyp4a10, Abca1, and Slc25a36 (Figure 3).
Discussion
In this study we set out to determine the effect of fasting
on several aspects directly related to the primary function
of the small intestine; the selective absorption and metab-
olism of food components. We find that of all genes
encoding transport proteins and phase I/II metabolic
enzymes, approximately 13% were changed due to 24
hours of fasting. Effects on gene expression are dependent
on the length of food deprivation, and PPARα is required
for the adaptive response of a subset of genes. A summary
of hypothetical functional outcomes of fasting in the
murine small intestine is presented in Figure 4, and
detailed below. Although in this study we only deter-
mined mRNA levels, it has been reported that for the
majority of genes the mRNA levels reflect protein abun-
dance very well [40,41]. We therefore allow ourselves to
speculate about the functional consequences of fasting.
Nevertheless, these implications should ultimately be
evaluated in follow-up studies.
Changes in intestinal structure upon fasting differ
between species [20]. Although we did not investigate this
in the current study, both Lenaerts et al. [42] and Chappell
et al. [43] observed only minor changes on murine
mucosal structure upon fasting. In addition, if occurring,
we believe that changes on tissue base do not affect our
gene expression data, because otherwise we should have
seen more pronounced differences on gene expression
level.
An array of intestinal transporters and phase I and II met-
abolic enzymes are required to handle adequately various
endogenous molecules, food components including
Table 4: Differential expressed detoxification genes in the small intestine after 24 h fasting.
Gene symbol Affy probe set ID A value SD WT 0 hr SD WT 24 hr Fold change P-value Gene name
CYPP450s
Cyp4a10 1424853_s_at 7.4 0.96 0.37 3.6 0.0019 Cytochrome P450, family 4, subfamily a, 
polypeptide 10
Cyp27a1 1417590_at 8.4 0.12 0.50 3.1 0.0001 Cytochrome P450, family 27, subfamily a, 
polypeptide 1
Cyp2j6 1417952_at 8.3 0.22 0.11 2.3 0.0000 Cytochrome P450, family 2, subfamily j, 
polypeptide 6
Cyp4b1 1416194_at 9.7 0.20 0.22 2.2 0.0000 Cytochrome P450, family 2, subfamily c, 
polypeptide 29
Cyp3a11 1416809_at 11.0 0.07 0.10 1.3 0.0057 Cytochrome P450, family 3, subfamily a, 
polypeptide 11
GSTs
Mgst1 1415897_a_at 11.1 0.05 0.08 1.3 0.0014 Microsomal glutathione S-transferase 1
Gstp1 1449575_a_at 11.9 0.14 0.13 -1.4 0.0027 Glutathione S-transferase, pi 1
Gstm5 1416842_at 7.1 0.12 0.05 -1.5 0.0002 Glutathione S-transferase, mu 5
Gstt1 1418186_at 7.1 0.21 0.06 -1.7 0.0001 Glutathione S-transferase, theta 1
Gstm3 1427473_at 5.4 0.44 0.45 -2.6 0.0006 Glutathione S-transferase, mu 3
Gstm4 1424835_at 4.5 0.60 0.38 -2.7 0.0009 Glutathione S-transferase, mu 4
Gstm3 1427474_s_at 9.2 0.36 0.79 -2.8 0.0027 Glutathione S-transferase, mu 3
SULTs
Sult1d1 1418138_at 9.9 0.15 0.33 1.7 0.0017 Sulfotransferase family 1D, member 1
Chst4 1453393_a_at 4.7 0.04 0.08 1.4 0.0008 Carbohydrate (chondroitin 6/keratan) 
sulfotransferase 4
AKRs
Akr1b7 1423556_at 10.3 0.04 0.63 2.5 0.0008 Aldo-keto reductase family 1, member B7
A = the average log2 transformed expression value of normal fed and 24 hours fasted mice (n = 3), SD = standard deviation (n = 3), WT = wild-type mice.
Table 5: Differential expressed ABC transporters in the small intestine after 24 h fasting.
Gene 
symbol
Affy probe 
set ID
A 
value
SD WT 0 
hr
SD WT 
24 hr
Fold 
change
P-value Localization Gene name
Abca1 1421840_at 6.266 0.28 0.44 2.3 0.0005 Basolateral (secretion) ATP-binding cassette, sub-family A (ABC1), member 1
Abcg8 1420656_at 8.037 0.18 0.25 1.8 0.0003 Apical (secretion) ATP-binding cassette, sub-family G (WHITE), member 8
A = the average log2 transformed expression value of normal fed and 24 hours fasted mice (n = 3), SD = standard deviation, WT = wild-type mice. In addition to the fold 
change, the intracellular localization of the corresponding protein is given.BMC Genomics 2007, 8:267 http://www.biomedcentral.com/1471-2164/8/267
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nutrients and xenobiotics. Our finding that 24 hours of
fasting results in the differential expression of 13% of the
transporter and phase I/II metabolism genes has implica-
tions for metabolism of the different types of substrates.
Regulation of genes involved in intestinal motility
Expression of the serotonin transporter Sert was increased
after 24 hours of fasting. Serotonin, a neurotransmitter
secreted by enterochromaffin cells, is considered to play a
key role in normal functioning of the gut, initiating peri-
staltic reflex pathways and facilitating propulsive activity.
Sert-mediated uptake of serotonin in enterocytes is
responsible for the termination of the action of serotonin
in the intestine [28]. After a meal, the small intestine
exhibits a pattern of phasic contractions of various ampli-
tudes [44]. During fasting, these phasic contractions are
replaced by a cyclic pattern with less frequent contrac-
tions, enough to propel undigested food residues and
sloughed enterocytes. As it is known that serotonin
increases the frequency of intestinal contractions [45],
removal of serotonin by Sert preserves these lower motil-
ity reflexes during fasting. Sult1d1 is involved in the sulfa-
tion of serotonin for the serotonin removal in enterocytes
[46]. For this conjugation the activated form of sulphate,
PAPS, is needed. Sult1d1, the apical sulphate transporter
Dtd, and the PAPS transporter Papst2 were all upregulated
during fasting. We believe that the coordinated induction
of these enzymes is required to maintain the lower peri-
staltic reflexes during fasting (Figure 4B).
Regulation of genes involved in metabolism of energy-
yielding substrates
Fasting increased the expression of Cact and Fatp2, and
G6pt1, three intracellular SLC transporters involved in
transport of substrates of mitochondrial β-oxidation and
glycogenolysis, respectively [30,31,33,47]. Changes in
gene expression of these transporters coincided with dif-
ferential gene expression of enzymes involved in both
processes (data not shown). In addition, the increased
expression of Cyp4a10 and Cyp4b1 points to enhanced
peroxisomal oxidation of fatty acids [11], and an elevated
level of Nadc1  implies increased uptake from luminal
dicarboxylates (Krebs cycle intermediates) as well as cit-
rate secreted by pancreatic and gastric juice [48]. Thus,
these changes reflect the molecular events caused by the
switch of fuel utilization from carbohydrates to fatty acid
oxidation (Figure 4A).
Regulation of genes involved in cholesterol efflux
Cholesterol can be secreted from enterocytes by chylomi-
crons and by the efflux transporters Abca1 and Abcg5/g8.
Expression of the cholesterol efflux transporters Abca1 and
Abcg8 was increased upon fasting. Since both carriers are
LXR target genes [49,50] we believe this is due to the pro-
foundly increased expression levels of Cyp27a1, which
results in enhanced levels of the potent LXR agonist 27-
hydroxycholesterol [51]. Since during fasting no choles-
terol is required for chylomicron formation, we speculate
this may be a compensatory mechanism for the enterocyte
to balance its intracellular cholesterol concentrations (Fig-
ure 4C).
Regulation of genes involved in metabolism of xenobiotics
Various CypP450s with well-known drug-metabolizing
capacity were differentially expressed after fasting (Cyp2j6,
Cyp3a11, and Cyp4b1). Increased expression of Cyp3a11
after fasting has also been observed in rat liver [52].
Although  Cyp3a11  does not have a direct human
ortholog, it has similar substrate specificity as human
CYP3A4. CYP3A4 is considered to be the major metabo-
lizing enzyme of approximately half of the drugs in use
Blood glucose levels, free fatty acid levels, and small intestinal weight during fasting Figure 1
Blood glucose levels, free fatty acid levels, and small intestinal weight during fasting. Significance was determined 
using an unpaired student's t-test. * P-value < 0.05. Bars represent standard error.
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Time dependent changes in gene expression during fasting Figure 2
Time dependent changes in gene expression during fasting. The horizontal axis indicates the hours of fasting. Signifi-
cance was determined using an unpaired student's t-test. * P-value < 0.05. Data are presented as mean ± standard error, n = 6–
10. qRT-PCR results of SLC transporters. (B) qRT-PCR results of detoxification genes. (C) qRT-PCR results of ABC transport-
ers.
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today [53]. Our results indicate that upon a fasting period
drugs may be more efficiently detoxified (Figure 4D),
which is of relevance e.g. during surgical interventions in
patients.
Except for Gsts, which were expressed at reduced levels,
fasting had no denoting effect on expression of phase II
metabolism genes. GSH plays an important role in the
defense against oxidative stress [54], and is required as
cofactor for glutathione peroxidase (GPx) and glutathione
S-transferase (Gst) activity. GPx detoxifies peroxides using
GSH as an electron donor, producing GSSG as end prod-
uct which in turn is converted back into GSH by glutath-
ione reductase (Gsr). Gsts catalyze the conjugation of
GSH to a wide variety of endogenous and exogenous elec-
trophilic compounds. It is known that upon fasting levels
of GSH are reduced in small intestine and liver [55-57],
likely as a result of increased oxidation and decreased
presence of its dietary precursory amino acids [58]. We
believe these reduced GSH levels may be responsible for
the observed reduced mRNA levels of the glutathione S-
transferase (Gsts), since it is known that expression levels
of Gsts are directly dependent on the presence of GSH
[59]. In addition, it is known that dietary electrophiles are
able to activate the transcription factor Nrf2, which can
activate among others Gsts [60]. During fasting these die-
tary electrophiles are not available, which may be an addi-
tional explanation for the reduced expression levels of
Gsts. The time dependent fasting experiment showed that
the reduction of Gstm3  is a very acute process. Thus,
regardless the underlying mechanism, the reduced GSH
and Gsts levels will render the fasting gut more sensitive
towards electrophilic stressors and other Gst substrates,
which may have implications for humans on drug therapy
during fasting and the period directly thereafter (Figure
4E).
Role of PPARα during fasting
We showed that eight of the transporters and phase I/II
metabolism genes were PPARα dependently regulated
during fasting (Figure 4F). Genes that were most promi-
nently regulated by PPARα were involved in lipid metab-
olism (Cyp4a10, Abca1, and Smct1). In liver Cyp4a10 and
Abca1 are known to be regulated via PPARα during fasting
[61,62]. Furthermore, Cyp4a10 is a known PPARα target
gene [63]. It has also been reported that Abca1 is regulated
by PPARα [64], although no PPAR responsive elements
have been identified in its promoter region [65]. Sert and
Dtd were PPARα dependently regulated, which indicates
that PPARα may link nutritional status to peristaltic
movement. Sert, Dtd, Slc25a36, Smct1, Chst4, and Mgst1
have all not been identified yet as PPARα target genes. We
conclude that PPARα is required for the adaptive response
of a subset of genes.
Conclusion
In this study we provide an overview of the effects of fast-
ing on expression of transporter and phase I/II metabo-
lism genes in the small intestine. Twenty-four hours of
fasting had a high impact on gene expression of murine
small intestinal transporter and phase I/II metabolism
genes. In addition, we demonstrated that the effects on
gene expression are dependent on the length of food dep-
rivation. Affected processes can functionally be summa-
qRT-PCR results of PPARα dependently regulated genes dur- ing fasting Figure 3
qRT-PCR results of PPARα dependently regulated 
genes during fasting. White bars represent the control 
group, black bars represent the 24 hours fasted group. Signif-
icance was determined using an unpaired student's t-test. * P-
value < 0.05. Data are presented as mean ± standard error, n 
= 3.
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Table 6: PPARα regulated genes during fasting.
Gene Symbol Probe Set ID FC WTc vs WT 24 hr P-value WT FC KOc vs KO 24 hr A value WT
Cyp4a10 1424853_s_at 3.6 0.0019 NC 7.4
Abca1 1421840_at 2.3 0.0005 NC 6.3
Slc25a36 1419656_at 1.7 0.0002 NC 6.7
Slc25a36 1419657_a_at 1.5 0.0007 NC 9.4
Smct1, Slc5a8 1425606_at 1.5 0.0009 NC 6.5
Sert, Slc6a4 1417150_at 1.4 0.0014 NC 8.5
Dtd, Slc26a2 1421145_at 1.4 0.0028 NC 5.6
Chst4 1453393_a_at 1.4 0.0008 NC 4.7
Mgst1 1415897_a_at 1.3 0.0014 NC 11.1
FC = Fold change, WT = wild-type mice. KO = PPARα-null mice, A = the average log2 transformed expression value of normal fed (c) and 24 hours (24 hr) fasted 
mice (n = 3).BMC Genomics 2007, 8:267 http://www.biomedcentral.com/1471-2164/8/267
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rized as a) increased oxidation of fat and xenobiotics, b)
increased activation of PPARα, c) increased cholesterol
secretion, d) increased susceptibility to electrophilic stres-
sors, and e) reduced intestinal motility. Finally, we
showed that PPARα mediates a part of the adaptive
response to fasting.
Methods
Animals
Pure bred wild-type (129S1/SvImJ) and PPARα-null
(129S4/SvJae) mice [66] were purchased from Jackson
Laboratories (Bar Harbor, ME) and bred at the animal
facility of Wageningen University. Mice were housed in a
light- and temperature-controlled facility and had free
access to water and standard laboratory chow (RMH-B,
Hope Farms, Woerden, the Netherlands). All animal stud-
ies were approved by the Local Committee for Care and
Use of Laboratory Animals.
Experimental design and tissue handling
Three to four month old male PPARα-null and wild-type
mice were fasted for several time points up to 24 hours.
Fasting experiments started at the onset of the light cycle.
Mice were anaesthetized with a mixture of isofluorane
(1.5%), nitrous oxide (70%) and oxygen (30%). Blood
was collected via orbital puncture, plasma was obtained
by centrifuging at 200 g for 10 minutes and stored at -
80°C until use. The small intestines were excised, flushed
with ice-cold PBS, and weighted. Remaining fat and pan-
creatic tissue was carefully removed and the small intes-
tine was snap-frozen in liquid nitrogen and stored at -
80°C until RNA isolation.
RNA isolation and quality control
Total RNA was isolated from small intestinal samples
using TRIzol reagent (Invitrogen, Breda, the Netherlands)
according to the manufacturer's instructions. RNA was
treated with DNAse and purified using the SV total RNA
isolation system (Promega, Leiden, the Netherlands).
Concentrations and purity of RNA samples were deter-
mined on a NanoDrop ND-1000 spectrophotometer (Iso-
gen, Maarssen, the Netherlands). RNA integrity was
checked on an Agilent 2100 bioanalyzer (Agilent Technol-
ogies, Amsterdam, the Netherlands) with 6000 Nano
Chips according to the manufacturer's instructions. RNA
was judged as suitable for array hybridization only if sam-
ples exhibited intact bands corresponding to the 18S and
28S ribosomal RNA subunits, and displayed no chromo-
somal peaks or RNA degradation products.
Affymetrix GeneChip oligoarray hybridization and 
scanning
For microarray analyses, we used RNA isolated from the
full-length small intestine. RNA was hybridized on an
Affymetrix GeneChip Mouse Genome 430A array. This
array detects 22,690 transcripts that represent 12,453
known genes. For each experimental group, three biolog-
ical replicated were hybridized, thus in total 12 arrays
were used. Detailed methods for the labeling and subse-
quent hybridizations are available on request. Arrays were
Hypothetical schematic overview of effects of fasting on small intestinal transporters and phase I/II metabolism genes Figure 4
Hypothetical schematic overview of effects of fasting on small intestinal transporters and phase I/II metabo-
lism genes. Not all results are summarized in this figure. The direction of transport is shown (↑) in the transporters, + means 
upregulated and – means downregulated during fasting. (A) Increased energy metabolism. (B) Diminished intestinal motility. (C) 
Elevated cholesterol secretion. (D) Increased xenobiotic metabolism. (E) Diminished capability of detoxification. (F) PPARα 
dependent regulated genes.
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scanned on a GeneChip Scanner 3000 (Affymetrix). Array
data have been submitted to the Gene Expression Omni-
bus, accession number GSE6864.
Analyses of microarray data
Scans of the Affymetrix arrays were processed using pack-
ages from the Bioconductor project [67]. Expression levels
of probe sets were estimated using the library GCRMA
[68], where after differentially expressed probe sets were
identified using linear models [69]. The library LIMMA
implements an empirical Bayes method to assign differen-
tial gene expression, an approach repeatedly shown to be
the most appropriate [70-73]. To compile a list of trans-
porter and phase I/II metabolism genes present on the
array, annotation information from Affymetrix (release of
July 2006) was queried for SLC transporters, ABC trans-
porters, CypP450s, the phase II metabolism enzymes glu-
tathione S-transferases, sulfotransferases, epoxide
hydrolases, aldo-keto reductases, N-acetyltransferases,
and glucuronosyl transferases. Also glutathione reductase,
glutathione synthetase, and glutathione peroxidases were
included in this set. The final set consisted of 665
probesets, encoding for 436 unique genes (Table 1). To
study significantly expressed genes, only probesets with
an expression value higher than 20 in the WT control
group were selected for further analysis. This filtering was
done after normalization. Probe sets that satisfied the cri-
terion of >1.3 fold change with a p-value < 0.01 were con-
sidered to be significantly regulated. Of these, probe sets
that were not changed in fasted PPARα-knockout mice,
were designated PPARα regulated. Interpretations of func-
tional outcomes of fasting focused on groups of genes that
are known to be functionally related (i.e. participating in
the same pathway or having a similar function). Although
at first sight the fold change threshold may seem to be
low, we could confirm all changes in gene expression
identified on the microarray (Table 2). Moreover, we
would like to stress that it is generally accepted that effects
of nutritional interventions on gene expression are subtle,
in contrast to pharmacological-type of interventions [74-
76]. A clear example of this is found in Patsouris et al.
[10], in which the effect of pharmacological, physiologi-
cal, and nutritional intervention on expression of the
same set of genes were compared.
Quantitative Real-time PCR
Single-stranded complementary DNA (cDNA) was syn-
thesized from 1 µg of total RNA using the Reverse tran-
scription system (Promega, Leiden, The Netherlands)
following the supplier's protocol. cDNA was PCR ampli-
fied with Platinum Taq DNA polymerase (all reagents
were from Invitrogen). Primer sequences used in the PCR
reaction were chosen based on the sequences available in
GenBank. The sequence of primers used is available in
Table 7. PCR was carried out using SYBR green on a MyIQ
thermal cycler (Bio-Rad laboratories BV, Veenendaal, The
Netherlands) with the following thermal cycling condi-
tions: 8 min at 94°C, followed by 45 cycles of 94°C for 15
s and 60°C for 1 min. All samples were performed in
duplicate and normalized to cyclophilin expression.
Free fatty acids and blood glucose levels
Free fatty acids were measured with the Free fatty acids
half-micro test (Roche Diagnostics, Almere, The Nether-
Table 7: Primer sequences.
Gene symbol Forward primer Reverse primer
Abca1 CCCAGAGCAAAAAGCGACTC CCCAGAGCAAAAAGCGACTC
Abcg8 AGTGGTCAGTCCAACACTCTG GAGACCTCCAGGGTATCTTGAA
Chst4 GTCTTTGATGCCTACATGAACCC GTGGGCAGGGAAGAAGTCA
Cyclophilin CAGACGCCACTGTCGCTTT TGTCTTTGGAACTTTGTCTGCAA
Cyp2j6 TTAGCCACGATCTGGGCAG CTGGGGGATAGTTCTTGGGG
Cyp3a11 TGAAACCACCAGTAGCACACTT CAGGTATTCCATCTCCATCACA
Cyp4a10 ACCACAATGTGCATCAAGGAGGCC AGGAATGAGTGGCTGTGTCGGGGAGAG
Cyp27a1 GCCTTGCACAAGGAAGTGACT CGCAGGGTCTCCTTAATCACA
Dtd AAGAGCAGCATGACCTCTCAC CTGCCTCAAGTCAGTGCCT
Fatp2 ACAACATTCGTGCCAAGTCTCT CTCCTCCACAGCTTCTTGTAGATC
G6pt1 GGCTACGGCTACTATCGCAC AGGAGGGCATGACAAAGGAGA
Gstm3 CCCCAACTTTGACCGAAGC GGTGTCCATAACTTGGTTCTCCA
Mct4 GAGGTGGTTCATACCCCGGAAA ATATGAGCGTTGCCCAGTCTCT
Mgst1 TCGCACTGACGAGAAGGTG TGCATGAGGGCTGTAGAGAGA
Nadc1 TCACAGCCTTCCTCTCCATGT ACTATTGCCTTCCTCCACATCCT
Slc25a28 AGCATTGCGTGATGTACCCG CCTGTTGCTGTGACGTTCA
Slc25a36 GTGAACCGAGTAGTGTCCCCT CCTTGCAGTTTGAATAAGCAGC
Sult1d1 ATGTCTTCAGGAGGGAGTTAGTG CATCAGGCCGGGCTTCAAA
Zip4 ATGCTCCCAAAGTCGGTCAC CAGCGTATTTAACAGGCCGTC
Znt2 AACTGCCAGGCGTGCCAGGG CCGTGGAGTGGTCCAGGCTGTGBMC Genomics 2007, 8:267 http://www.biomedcentral.com/1471-2164/8/267
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lands) according to the manufacturer's instructions.
Blood glucose levels were determined by the Accu-Chek
Compact Glucose (Roche Diagnostics, Almere, The Neth-
erlands) with 1 drop of blood obtained by orbital punc-
ture.
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